These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23253777)

  • 1. Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods.
    Hobart J; Cano S; Posner H; Selnes O; Stern Y; Thomas R; Zajicek J;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S4-9. PubMed ID: 23253777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.
    Cano SJ; Posner HB; Moline ML; Hurt SW; Swartz J; Hsu T; Hobart JC
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1363-8. PubMed ID: 20881017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory.
    Hobart J; Cano S; Posner H; Selnes O; Stern Y; Thomas R; Zajicek J;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S10-20. PubMed ID: 23253779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
    Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
    Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach.
    Posner HB; Cano S; Carrillo MC; Selnes O; Stern Y; Thomas RG; Zajicek J; Hobart J;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S56-60. PubMed ID: 23391006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
    Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
    Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
    Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
    J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TE4D-Cog: a new test for detecting early dementia in English-speaking populations.
    Mahoney R; Johnston K; Katona C; Maxmin K; Livingston G
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1172-9. PubMed ID: 16315149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID).
    Verhey FR; Houx P; Van Lang N; Huppert F; Stoppe G; Saerens J; Böhm P; De Vreese L; Nordlund A; DeDeyn PP; Neri M; Peña-Casanova J; Wallin A; Bollen E; Middelkoop H; Nargeot MC; Puel M; Fleischmann UM; Jolles J
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):41-50. PubMed ID: 14716698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial.
    Weyer G; Erzigkeit H; Kanowski S; Ihl R; Hadler D
    Int Psychogeriatr; 1997 Jun; 9(2):123-38. PubMed ID: 9309486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS - cog, SKT and MMSE.
    Ihl R; Grass-Kapanke B; Jänner M; Weyer G
    Pharmacopsychiatry; 1999 Nov; 32(6):248-54. PubMed ID: 10599935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and concurrent validity of Alzheimer's disease assessment scale - Cognitive subscale, Chinese version (ADAS-Cog-C) among Chinese community-dwelling older people population.
    Jiang Y; Yang H; Zhao J; Wu Y; Zhou X; Cheng Z
    Clin Neuropsychol; 2020 Dec; 34(sup1):43-53. PubMed ID: 32279575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
    Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
    Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.